In Vitro Maturation (IVM) of Human Oocytes

Weill Medical College of Cornell University1 site in 1 country2 target enrollmentFebruary 15, 2012

ConditionsInfertility

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Infertility
Sponsor: Weill Medical College of Cornell University
Enrollment: 2
Locations: 1
Primary Endpoint: number of oocytes retrieved and embryos generated
Status: Terminated
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The objectives of this study are to evaluate the clinical efficacy of Natural in vitro Fertilization and in vitro maturation.

Detailed Description

Collection of one mature egg from a follicle in the ovary without gonadotropin medications (natural cycle IVF) results in low pregnancy rates. One way to improve natural cycle IVF is to combine this procedure with the removal of immature eggs from the ovary and mature these eggs in the laboratory ( in vitro maturation-IVM). The in vitro mature eggs are fertilized and the resultant embryos are cultured using conventional IVF techniques.

Registry

clinicaltrials.gov

Start Date

February 15, 2012

End Date

September 18, 2023

Last Updated

2 years ago

Study Type

Interventional

Study Design

Single Group

Sex

Female

Investigators

Sponsor

Weill Medical College of Cornell University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Each subject must be female.
•Each subject must have an indication for COH and IVF with or without ICSI.
•Each subject must be willing and able to provide written informed consent for the trial
•Each subject must be 25 to ≤42 years of age at the time of signing informed consent.
•Each subject must have a normal cervical smear result (no atypical or abnormal cells, or in case of atypical squamous or glandular cells, no signs of malignancy; corresponding to Papanicolaou \[PAP\] I or II) obtained within 12 months prior to signing informed consent must be available

Exclusion Criteria

•Subject with premature ovarian failure
•Subject with endocrine abnormalities such as hyperprolactinaemia or thyroid dysfunction
•Subject with malformation or absence of uterus
•Subject has tested positive for Human Immunodeficiency Virus (HIV) or Hepatitis B (by local laboratory; results obtained within 1 year prior to signing ICF are considered valid).
•Subject with contraindication or allergy/hypersensitivity to hCG, estrogen and progesterone